Chemotherapy Induced Anemia Market By Grade, By Treatment, By End User : Global Opportunity Analysis and Industry Forecast, 2023-2032

Description

List of Tables

According to a new report published by Allied Market Research, titled, "Chemotherapy Induced Anemia Market," The chemotherapy induced anemia market was valued at $2.7 billion in 2022, and is estimated to reach $5 billion by 2032, growing at a CAGR of 6.3% from 2023 to 2032. Chemotherapy-induced anemia (CIA) is a specific type of anemia that occurs as a side effect of chemotherapy treatment for cancer. Chemotherapy drugs can disrupt the normal functioning of the bone marrow, which is responsible for producing red blood cells. As a result, there is a decrease in the number of red blood cells circulating in the body, leading to anemia. CIA can cause various symptoms such as fatigue, weakness, shortness of breath, dizziness, and pale skin. These symptoms can significantly impact the quality of life and overall well-being of cancer patients undergoing chemotherapy. The treatment of CIA includes blood transfusion, erythropoiesis-stimulating agents (ESAs), and iron & other Iron supplementation.

Chemotherapy Induced Anemia Market - IMG1

The chemotherapy induced anemia market growth is driven by increase in prevalence of cancer, rise in demand for targeted therapies, and surge in aging population. The increasing prevalence of cancer and the associated use of chemotherapy is expected to continue to drive the growth of the chemotherapy-induced anemia market. For instance, in February 2022, the World Health Organization (WHO) estimated that approximately 400,000 children develop cancer every year across the globe. In addition, a study conducted by the National Center for Biotechnology Information (NCBI) in April 2022 estimated the occurrence rate of anemia was about 41.1% in patients suffering from breast cancer. Therefore, the rise in prevalence of cancer drives the growth of the market. In addition, older people are more likely to develop cancer and anemia, which further fuels the demand for drugs to treat chemotherapy induced anemia.

Rise in demand for chemotherapy induced anemia is the key factor driving the growth of chemotherapy induced anemia market. This is attributed to an increase in appearance of anemia, rise in ageing population, and availability of effective treatment. The aging population is more susceptible to developing cancer, leading to a higher demand for CIA treatment. In addition, development of new and more effective treatments for CIA, including erythropoiesis-stimulating agents (ESAs) and iron supplementation, has expanded the options available for managing anemia during chemotherapy. Iron supplement is an effective treatment for chemotherapy induced anemia as it has low side-effects as compared with other treatment options.

For instance, in October 2022, the World Health Organization (WHO) estimated that the global population aged 60 years and over is expected to double by 2050 to reach 2.1 billion. Moreover, according to the National Center for Biotechnology Information (NCBI), older adults are more likely to experience anemia as a result of cancer treatment. Furthermore, increase in awareness about chemotherapy induced anemia among patients and healthcare professionals has led to an increase in the number of patients seeking treatment for CIA. In addition, rise in government initiatives to improve cancer care and the treatment of chemotherapy-induced anemia (CIA) further propels the market growth. For instance, the federal government announced in May 2020 that it would be investing $150 million over five years in the Canadian Partnership against Cancer, with a focus on improving access to cancer care and support for patients. Thus, a rise in government initiatives further boosts the market growth.

However, the high cost of chemotherapy induced anemia therapies and side effects associated with the ESAs limit the adoption of these treatments, which negatively impacts the market growth. For instance, the cost of blood transfusion ranges from $200 to $300 per pint of blood. Thus, the high cost of blood transfusion and other drugs negatively impact market growth. On the other hand, development of novel therapies for the treatment of chemotherapy induced anemia with lower side effects and increase in R&D activities for developing advanced therapies are expected to create immense opportunities for the growth of chemotherapy induced anemia market during the forecast period. The chemotherapy induced anemia market is segmented on the basis of grade, treatment, end user, and region. On the basis of grade, the market is classified into grade 1, grade 2, and grade 3&4. As per treatment, the market is segmented into blood transfusion, erythropoietin-stimulating agents, and iron & other supplements.

On the basis of end user, the market is segmented into hospitals, cancer centers, and others. The other segment includes cancer research centers, cancer rehabilitation centers, and home use. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global chemotherapy induced anemia market are Pfizer Inc., Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche Ltd., Johnson & Johnson, Amgen Inc., Novartis AG, 3SBio Group, Bristol-Myers Squibb Company, FibroGen, Inc., and Astella Pharma

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the chemotherapy induced anemia market analysis from 2022 to 2032 to identify the prevailing chemotherapy induced anemia market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the chemotherapy induced anemia market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global chemotherapy induced anemia market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Grade

Grade 1
Grade 2
Grade 3 and 4

By Treatment

Blood transfusion
Erythropoiesis stimulating agents
- Type
- Long Acting Erythropoietin stimulating agents
- Short Acting Erythropoietin stimulating agents
Iron and others supplementation

By End User

Hospitals
Cancer center
Others

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

Dr. Reddy's Laboratories Ltd.
3SBio Group
Johnson & Johnson
FibroGen, Inc.
Novartis AG
Pfizer Inc.
Amgen Inc.
Astellas Pharma Inc.
F. Hoffmann-La Roche Ltd.
Bristol-Myers Squibb Company

Product Code: A10539

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. Bargaining power of suppliers
- 3.3.2. Bargaining power of buyers
- 3.3.3. Threat of substitutes
- 3.3.4. Threat of new entrants
- 3.3.5. Intensity of rivalry
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Increase in prevalence of cancer
  - 3.4.1.2. Increase in demand for chemotherapy induced anemia treatment

3.4.2. Restraints
- 3.4.2.1. High cost of chemotherapy induced anemia treatments
- 3.4.2.2. Side effects associated with erythropoiesis stimulating agents

3.4.3. Opportunities
- 3.4.3.1. Development of novel therapies

3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: CHEMOTHERAPY INDUCED ANEMIA MARKET, BY GRADE

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Grade 1
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. Grade 2
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
4.4. Grade 3 and 4
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country

CHAPTER 5: CHEMOTHERAPY INDUCED ANEMIA MARKET, BY TREATMENT

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Blood transfusion
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Erythropoiesis stimulating agents
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
- 5.3.4. Erythropoiesis stimulating agents Chemotherapy Induced Anemia Market by Type
5.4. Iron and others supplementation
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country

CHAPTER 6: CHEMOTHERAPY INDUCED ANEMIA MARKET, BY END USER

6.1. Overview
- 6.1.1. Market size and forecast
6.2. Hospitals
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. Cancer center
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
6.4. Others
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country

CHAPTER 7: CHEMOTHERAPY INDUCED ANEMIA MARKET, BY REGION

7.1. Overview
- 7.1.1. Market size and forecast By Region
7.2. North America
- 7.2.1. Key trends and opportunities
- 7.2.2. Market size and forecast, by Grade
- 7.2.3. Market size and forecast, by Treatment
- 7.2.4. Market size and forecast, by End User
- 7.2.5. Market size and forecast, by country
  - 7.2.5.1. U.S.
  - 7.2.5.1.1. Key market trends, growth factors and opportunities
  - 7.2.5.1.2. Market size and forecast, by Grade
  - 7.2.5.1.3. Market size and forecast, by Treatment
  - 7.2.5.1.4. Market size and forecast, by End User
  - 7.2.5.2. Canada
  - 7.2.5.2.1. Key market trends, growth factors and opportunities
  - 7.2.5.2.2. Market size and forecast, by Grade
  - 7.2.5.2.3. Market size and forecast, by Treatment
  - 7.2.5.2.4. Market size and forecast, by End User
  - 7.2.5.3. Mexico
  - 7.2.5.3.1. Key market trends, growth factors and opportunities
  - 7.2.5.3.2. Market size and forecast, by Grade
  - 7.2.5.3.3. Market size and forecast, by Treatment
  - 7.2.5.3.4. Market size and forecast, by End User
7.3. Europe
- 7.3.1. Key trends and opportunities
- 7.3.2. Market size and forecast, by Grade
- 7.3.3. Market size and forecast, by Treatment
- 7.3.4. Market size and forecast, by End User
- 7.3.5. Market size and forecast, by country
  - 7.3.5.1. Germany
  - 7.3.5.1.1. Key market trends, growth factors and opportunities
  - 7.3.5.1.2. Market size and forecast, by Grade
  - 7.3.5.1.3. Market size and forecast, by Treatment
  - 7.3.5.1.4. Market size and forecast, by End User
  - 7.3.5.2. France
  - 7.3.5.2.1. Key market trends, growth factors and opportunities
  - 7.3.5.2.2. Market size and forecast, by Grade
  - 7.3.5.2.3. Market size and forecast, by Treatment
  - 7.3.5.2.4. Market size and forecast, by End User
  - 7.3.5.3. UK
  - 7.3.5.3.1. Key market trends, growth factors and opportunities
  - 7.3.5.3.2. Market size and forecast, by Grade
  - 7.3.5.3.3. Market size and forecast, by Treatment
  - 7.3.5.3.4. Market size and forecast, by End User
  - 7.3.5.4. Italy
  - 7.3.5.4.1. Key market trends, growth factors and opportunities
  - 7.3.5.4.2. Market size and forecast, by Grade
  - 7.3.5.4.3. Market size and forecast, by Treatment
  - 7.3.5.4.4. Market size and forecast, by End User
  - 7.3.5.5. Spain
  - 7.3.5.5.1. Key market trends, growth factors and opportunities
  - 7.3.5.5.2. Market size and forecast, by Grade
  - 7.3.5.5.3. Market size and forecast, by Treatment
  - 7.3.5.5.4. Market size and forecast, by End User
  - 7.3.5.6. Rest of Europe
  - 7.3.5.6.1. Key market trends, growth factors and opportunities
  - 7.3.5.6.2. Market size and forecast, by Grade
  - 7.3.5.6.3. Market size and forecast, by Treatment
  - 7.3.5.6.4. Market size and forecast, by End User
7.4. Asia-Pacific
- 7.4.1. Key trends and opportunities
- 7.4.2. Market size and forecast, by Grade
- 7.4.3. Market size and forecast, by Treatment
- 7.4.4. Market size and forecast, by End User
- 7.4.5. Market size and forecast, by country
  - 7.4.5.1. Japan
  - 7.4.5.1.1. Key market trends, growth factors and opportunities
  - 7.4.5.1.2. Market size and forecast, by Grade
  - 7.4.5.1.3. Market size and forecast, by Treatment
  - 7.4.5.1.4. Market size and forecast, by End User
  - 7.4.5.2. China
  - 7.4.5.2.1. Key market trends, growth factors and opportunities
  - 7.4.5.2.2. Market size and forecast, by Grade
  - 7.4.5.2.3. Market size and forecast, by Treatment
  - 7.4.5.2.4. Market size and forecast, by End User
  - 7.4.5.3. Australia
  - 7.4.5.3.1. Key market trends, growth factors and opportunities
  - 7.4.5.3.2. Market size and forecast, by Grade
  - 7.4.5.3.3. Market size and forecast, by Treatment
  - 7.4.5.3.4. Market size and forecast, by End User
  - 7.4.5.4. India
  - 7.4.5.4.1. Key market trends, growth factors and opportunities
  - 7.4.5.4.2. Market size and forecast, by Grade
  - 7.4.5.4.3. Market size and forecast, by Treatment
  - 7.4.5.4.4. Market size and forecast, by End User
  - 7.4.5.5. South Korea
  - 7.4.5.5.1. Key market trends, growth factors and opportunities
  - 7.4.5.5.2. Market size and forecast, by Grade
  - 7.4.5.5.3. Market size and forecast, by Treatment
  - 7.4.5.5.4. Market size and forecast, by End User
  - 7.4.5.6. Rest of Asia-Pacific
  - 7.4.5.6.1. Key market trends, growth factors and opportunities
  - 7.4.5.6.2. Market size and forecast, by Grade
  - 7.4.5.6.3. Market size and forecast, by Treatment
  - 7.4.5.6.4. Market size and forecast, by End User
7.5. LAMEA
- 7.5.1. Key trends and opportunities
- 7.5.2. Market size and forecast, by Grade
- 7.5.3. Market size and forecast, by Treatment
- 7.5.4. Market size and forecast, by End User
- 7.5.5. Market size and forecast, by country
  - 7.5.5.1. Brazil
  - 7.5.5.1.1. Key market trends, growth factors and opportunities
  - 7.5.5.1.2. Market size and forecast, by Grade
  - 7.5.5.1.3. Market size and forecast, by Treatment
  - 7.5.5.1.4. Market size and forecast, by End User
  - 7.5.5.2. Saudi Arabia
  - 7.5.5.2.1. Key market trends, growth factors and opportunities
  - 7.5.5.2.2. Market size and forecast, by Grade
  - 7.5.5.2.3. Market size and forecast, by Treatment
  - 7.5.5.2.4. Market size and forecast, by End User
  - 7.5.5.3. South Africa
  - 7.5.5.3.1. Key market trends, growth factors and opportunities
  - 7.5.5.3.2. Market size and forecast, by Grade
  - 7.5.5.3.3. Market size and forecast, by Treatment
  - 7.5.5.3.4. Market size and forecast, by End User
  - 7.5.5.4. Rest of LAMEA
  - 7.5.5.4.1. Key market trends, growth factors and opportunities
  - 7.5.5.4.2. Market size and forecast, by Grade
  - 7.5.5.4.3. Market size and forecast, by Treatment
  - 7.5.5.4.4. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

9.1. Pfizer Inc.
- 9.1.1. Company overview
- 9.1.2. Key Executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
9.2. Dr. Reddy's Laboratories Ltd.
- 9.2.1. Company overview
- 9.2.2. Key Executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
9.3. Johnson & Johnson
- 9.3.1. Company overview
- 9.3.2. Key Executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
9.4. Amgen Inc.
- 9.4.1. Company overview
- 9.4.2. Key Executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Business performance
9.5. Novartis AG
- 9.5.1. Company overview
- 9.5.2. Key Executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
9.6. 3SBio Group
- 9.6.1. Company overview
- 9.6.2. Key Executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
9.7. FibroGen, Inc.
- 9.7.1. Company overview
- 9.7.2. Key Executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
9.8. Astellas Pharma Inc.
- 9.8.1. Company overview
- 9.8.2. Key Executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
9.9. Bristol-Myers Squibb Company
- 9.9.1. Company overview
- 9.9.2. Key Executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
9.10. F. Hoffmann-La Roche Ltd.
- 9.10.1. Company overview
- 9.10.2. Key Executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance